Citius pharmaceuticals receives fda approval for lymphir™ (denileukin diftitox-cxdl) immunotherapy for the treatment of adults with relapsed or refractory cutaneous t-cell lymphoma

Only systemic treatment for relapsed or refractory (r/r) ctcl to target the il-2 receptor on malignant t-cells and tregs lymphir is expected to launch within the next five months lymphir's approval marks the first novel targeted systemic therapy approved by the fda r/r ctcl since 2018 approval based on phase 3 pivotal study 302 results that demonstrated 36% orr, reduction in skin disease in 84% of patients, clinically significant pruritis improvement, and no cumulative toxicity cranford, n.j. , aug. 8, 2024 /prnewswire/ -- citius pharmaceuticals, inc. (nasdaq: ctxr) ("citius", "citius pharma"), announced today that the u.s. food and drug administration (fda) has approved lymphir™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous t-cell lymphoma (ctcl) after at least one prior systemic therapy.
CTXR Ratings Summary
CTXR Quant Ranking